This firm has 3.54
M in debt. The company has a current ratio of 0.09, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.
On a scale of 0 to 100, Regencell Bioscience holds a
performance score of 6. The company holds a Beta of 1.4893, which implies a somewhat significant risk relative to the market. Let's try to break down what Regencell's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Regencell Bioscience will likely underperform. Although it is vital to follow
Regencell Bioscience current trending patterns, it is good to be conservative about what you can do with the information regarding equity existing
price patterns. The philosophy towards forecasting
future performance of any stock is to evaluate the business as a whole together with its past performance, including all
available fundamental and
technical indicators. We have found twenty-eight
technical indicators for Regencell Bioscience, which you can use to evaluate the performance of the company. Please employ Regencell Bioscience
jensen alpha,
potential upside,
accumulation distribution, as well as the
relationship between the
treynor ratio and
expected short fall to make a quick decision on whether Regencell Bioscience historical
price patterns will revert.
We determine the current worth of Regencell Bioscience Holdings using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Regencell Bioscience based exclusively on its
fundamental and basic
technical indicators. By analyzing Regencell Bioscience's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of
Regencell Bioscience's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Regencell Bioscience. We calculate exposure to Regencell Bioscience's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Regencell Bioscience's related companies.
Regencell Bioscience Investment Alerts
Regencell investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Regencell Bioscience Holdings performance across your portfolios.Please check all
investment alerts for Regencell
Regencell Bioscience Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Regencell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Regencell Bioscience competition to find
correlations between indicators driving the intrinsic value of Regencell.
What is driving Regencell Bioscience Investor Appetite?
Regencell Bioscience reported the last year's revenue of 3.11
B. Reported Net Loss for the year was (848.2
K) with profit before taxes, overhead, and interest of 1.97
B.
Margins Breakdown
Regencell profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Regencell Bioscience itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Regencell Bioscience profit margins.
| Operating Margin | 9.24 |
| EBITDA Margin | 16.43 |
| Gross Margin | 54.86 |
| Profit Margin | 4.23 |
Regencell Bioscience Earnings Before Interest Taxes and Depreciation Amortization USD is increasing over the last 6 years. The previous year's value of Regencell Bioscience Earnings Before Interest Taxes and Depreciation Amortization USD was 678,871,711. Further, Regencell Bioscience Earnings Before Interest Taxes and Depreciation Amortization EBITDA is increasing over the last 5 years.
Our take on today Regencell Bioscience rise
Current variance is at 46.15. Regencell Bioscience Holdings is displaying above-average volatility over the selected time horizon. Investors should scrutinize Regencell Bioscience Holdings independently to ensure intended market timing strategies are aligned with expectations about Regencell Bioscience volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Regencell Bioscience's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Regencell Bioscience's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Regencell Bioscience Implied Volatility
Regencell Bioscience's implied volatility exposes the market's sentiment of Regencell Bioscience Holdings stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Regencell Bioscience's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Regencell Bioscience stock will not fluctuate a lot when Regencell Bioscience's options are near their expiration.
Our Conclusion on Regencell Bioscience
Whereas some firms under the drug manufacturers—specialty & generic industry are still a bit expensive, Regencell Bioscience may offer a potential longer-term growth to investors. In closing, as of the 4th of January 2022, our analysis shows that Regencell Bioscience responds to the market. The company is
overvalued and projects
very small odds of financial turmoil for the next 2 years. Our primary 90 days advice on the company is
Cautious Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Regencell Bioscience Holdings. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com